Indications

Non-Hodgkin’s Lymphoma (NHL)

RIABNI™ (rituximab-arrx) is indicated for the treatment of adult patients with:
- Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent.
- Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy.
- Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy.
- Previously untreated diffuse large B-cell, CD20-positive NHL in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens.
Chronic Lymphocytic Leukemia (CLL)

RIABNI™, in combination with fludarabine and cyclophosphamide (FC), is indicated for the treatment of adult patients with previously untreated and previously treated CD20-positive CLL.

BEHIND RIABNI™ The amgen experience YOU'VE COME to trust

Introducing Riabni™

The rituximab biosimilar from Amgen, a proven leader in oncology biologics¹

Introducing Riabni™

The rituximab biosimilar from Amgen, a proven leader in oncology biologics¹

RIABNI™ is FDA approved for all Rituxan® oncology indications^1,2

Non-Hodgkin's lymphoma (NHL)
- - Follicular lymphoma (FL)
- - Previously untreated large B-cell lymphoma
- - Non-progressing (stable disease)
Previously untreated chronic lymphocytic leukemia (CLL)

FDA = Food and Drug Administration.

BEHIND RIABNI™ The amgen experience YOU'VE COME to trust

BEHIND RIABNI™ The amgen experience YOU'VE COME to trust

Introducing Riabni™

The rituximab biosimilar from Amgen, a proven leader in oncology biologics1

Introducing Riabni™

The rituximab biosimilar from Amgen, a proven leader in oncology biologics1

RIABNI™ (rituximab-arrx) has anestablished Q-Code:

IMPORTANT SAFETY INFORMATION AND INDICATIONS

BOXED WARNINGS: FATAL INFUSION-RELATED REACTIONS, SEVERE MUCOCUTANEOUS REACTIONS, HEPATITIS B VIRUS REACTIVATION, PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY

Warnings and Precautions

Infusion-Related reactions (IRR)

Severe Mucocutaneous Reactions

Hepatitis B Virus Reactivation

Progressive Multifocal Leukoencephalopathy (PML)

Tumor Lysis Syndrome

Infections

Cardiovascular Adverse Reactions

Renal Toxicity

Bowel Obstruction and Perforation

Immunization

Embryo-Fetal Toxicity

Additional Important Safety Information

Adverse Reactions

Pregnancy and Nursing Mothers

Attention Healthcare Provider: Provide Medication Guide to patient prior to RIABNI™ infusion and advise patients to read guide.

INDICATIONS

Non-Hodgkin’s Lymphoma (NHL)

Chronic Lymphocytic Leukemia (CLL)

IMPORTANT SAFETY INFORMATION AND INDICATIONS

BOXED WARNINGS: FATAL INFUSION-RELATED REACTIONS, SEVERE MUCOCUTANEOUS REACTIONS, HEPATITIS B VIRUS REACTIVATION, PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY

Warnings and Precautions

Infusion-Related reactions (IRR)

Severe Mucocutaneous Reactions

Hepatitis B Virus Reactivation

Progressive Multifocal Leukoencephalopathy (PML)

Tumor Lysis Syndrome

Infections

Cardiovascular Adverse Reactions

Renal Toxicity

Bowel Obstruction and Perforation

Immunization

Embryo-Fetal Toxicity

Additional Important Safety Information

Adverse Reactions

Pregnancy and Nursing Mothers

Attention Healthcare Provider: Provide Medication Guide to patient prior to RIABNI™ infusion and advise patients to read guide.

Indications

Non-Hodgkin’s Lymphoma (NHL)

Chronic Lymphocytic Leukemia (CLL)

Connect with an Amgen Oncology representative

Privacy Statement

The rituximab biosimilar from Amgen, a proven leader in oncology biologics¹

The rituximab biosimilar from Amgen, a proven leader in oncology biologics¹

RIABNI™
(rituximab-arrx) has an
established Q-Code: